Anebulo Pharmaceuticals, Inc.
ANEB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ANEB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ANEB
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing selonabant, an investigational drug for acute cannabinoid overdose, with no revenue to date and a history of operating losses.
Key risk: No revenue and operating losses
BioSniper Score
Based on 4 of 6 signals
Financial data as of Dec 31, 2025.
Tracking 1 pipeline candidate · 2 clinical trials for Anebulo Pharmaceuticals, Inc..
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing selonabant, an investigational drug for acute cannabinoid overdose, with no revenue to date and a history of operating losses.
- Anebulo has not generated any revenue since inception [sec_mda · as of 2026-02-12].
- Cash and cash equivalents were $9.0M as of 2025-12-31 [sec].
- Net loss was $2.0M for the period ended 2025-12-31 [sec].
- Shareholders' equity was $11.7M as of 2025-12-31 [sec].
- The company expects its cash and cash equivalents at December 31, 2025, along with access to the Loan Agreement, to fund operations for at least the next 12 months [sec_mda · as of 2026-02-12].
What works
- Anebulo holds U.S. Patent No. 11,141,404 covering the use of selonabant to treat acute cannabinoid overdose, providing intellectual property protection [sec_mda · as of 2026-02-12].
- The company raised approximately $15.0 million in gross proceeds from a December 2024 private placement, strengthening its cash position [sec_mda · as of 2026-02-12].
- Management expects current cash and cash equivalents, plus available Loan Agreement funds, to support planned operations for at least 12 months from the filing of the latest quarterly report [sec_mda · as of 2026-02-12].
What to weigh
- Anebulo has incurred significant operating losses since inception in April 2020 and expects to continue incurring losses as it advances clinical development [sec_mda · as of 2026-02-12].
- The company has no revenue and cannot predict if, when, or to what extent it will generate revenue from product sales or collaborations [sec_mda · as of 2026-02-12].
- If the company were to delist from Nasdaq, it would continue as a public company trading on the OTC market, which may affect liquidity and visibility [sec_mda · as of 2026-02-12].
- The company's cash runway estimates are based on assumptions that may prove imprecise, and it may exhaust capital resources sooner than expected [sec_mda · as of 2026-02-12].
From the filings
Quoted directly from source documents.
Anebulo has not generated any revenue since inception.
“We have not generated any revenue since inception.”
SEC MD&A · February 12, 2026
The company holds a U.S. patent for treating acute cannabinoid overdose with selonabant.
“On October 12, 2021, the United States Patent and Trademark Office issued to us U.S. Patent No. 11,141,404, titled "Formulations and Methods For Treating Acute Cannabinoid Overdose."”
SEC MD&A · February 12, 2026
Anebulo raised approximately $15.0 million in a December 2024 private placement.
“we received aggregate gross proceeds from the December 2024 Private Placement of approximately $15.0 million.”
SEC MD&A · February 12, 2026
The company expects current cash to fund operations for at least 12 months.
“We expect that our cash and cash equivalents at December 31, 2025, along with access to the available amount under the Loan Agreement, will enable us to fund our current and planned operating expenses and capital expenditures for at least the next 12 months from the filing of this Quarterly Report.”
SEC MD&A · February 12, 2026
Risks & what to watch (4)›
Key risks
- No revenue and operating losses — Anebulo has no revenue and has incurred significant operating losses since inception [sec_mda · as of 2026-02-12].
- Cash runway uncertainty — Cash runway estimates are based on assumptions that may prove imprecise; capital may be exhausted sooner than expected [sec_mda · as of 2026-02-12].
- Nasdaq delisting risk — If delisted, the company would trade on OTC, potentially reducing liquidity and visibility [sec_mda · as of 2026-02-12].
- Clinical development risks — The company's future depends on successful clinical trials and regulatory approvals for selonabant, which are uncertain [sec_mda · as of 2026-02-12].
What to watch
- Progress and results of the ongoing SAD study and Phase 2 proof-of-concept trial for selonabant [sec_mda · as of 2026-02-12].
- Any updates on regulatory interactions with European agencies regarding the clinical trial protocol [sec_mda · as of 2026-02-12].
- Cash burn rate and any additional financing activities, given the company's history of private placements [sec_mda · as of 2026-02-12].
- Potential Nasdaq listing status and any actions taken to maintain compliance [sec_mda · as of 2026-02-12].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Anebulo Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Anebulo Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
20.8 months
D/E 0.19 · 0% dilution
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Short Interest
as of Apr 21, 2026- % of float
- 2.2%
- Days to cover
- 1.5
- Shares short
- 146,372
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ANEB short interestGovernance
Frequently asked questions
What is the AI investment thesis for Anebulo Pharmaceuticals, Inc.?
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing selonabant, an investigational drug for acute cannabinoid overdose, with no revenue to date and a history of operating losses.
What is Anebulo Pharmaceuticals, Inc.'s lead drug candidate?
Anebulo Pharmaceuticals, Inc.'s most advanced tracked candidate is selonabant (formerly ANEB-001) (Phase 2) for Healthy Volunteers.
Who is the CEO of Anebulo Pharmaceuticals, Inc.?
Mr. Richard Anthony Cunningham is the chief executive officer of Anebulo Pharmaceuticals, Inc. (ANEB).
Where is Anebulo Pharmaceuticals, Inc. headquartered?
Anebulo Pharmaceuticals, Inc. (ANEB) is headquartered in Lakeway, TX, United States.
What therapeutic areas does Anebulo Pharmaceuticals, Inc. focus on?
Anebulo Pharmaceuticals, Inc. develops therapies across Neurology, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.